Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study

Karyopharm Therapeutics said ​on Tuesday its ‌oncology therapy showed a ​statistically ​significant improvement in spleen ⁠volume ​in a late‑stage ​trial in patients with a ​rare blood ​cancer, one of ‌the ⁠study's main goals.